LBA93 EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)

医学 化疗 阶段(地层学) 安慰剂 肿瘤科 肺癌 内科学 随机对照试验 癌症 病理 替代医学 生物 古生物学
作者
Ying Cheng,Ying Liu,W. Zhang,Lin Wu,Caicun Zhou,Dan Wang,Bairong Xia,M. Bi,Xiaorui Fu,Chunde Li,G. Chen,Dongqing Lv,Yanqiu Zhao,Jianan Huang,Ming Li,T. Yi,Xiao‐Jun Huang,Runxiang Yang,Zewen Chen,Y. Wang
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1334-S1334 被引量:19
标识
DOI:10.1016/j.annonc.2023.10.096
摘要

Combinations of immunotherapy with chemotherapy as a first-line treatment for ES-SCLC have generated mixed results. The EXTENTORCH trial assessed toripalimab in combination with chemotherapy as a first-line treatment for patients with ES-SCLC (NCT04012606). Patients with histologically or cytologically confirmed ES-SCLC, stratified by gender and baseline ECOG PS (0 vs. 1) were randomized in a 1:1 ratio to receive 240 mg toripalimab or placebo plus etoposide and cisplatin/carboplatin Q3W for 4-6 cycles, followed by single-agent toripalimab or placebo until progressive disease, intolerable toxicity or up to 2-year treatment. The primary endpoints were PFS as assessed by the investigator per RECIST v1.1 and OS. Tumor mutational burden (TMB) and genomic alterations were assessed by whole-exome sequencing (WES) of tumor tissues. From Sep 2019 to May 2021, 442 patients were enrolled from 48 participating sites in China. 223 and 219 patients were randomized to the toripalimab and the placebo arms, respectively. At data cut off (28 Feb 2022), median follow-up was 11.8 months, a significant improvement in PFS was observed for toripalimab over placebo (5.8 vs. 5.6 months, HR = 0.667 [95% CI: 0.539-0.824], P = 0.0002). Despite 59.4% of patients in the placebo arm received ≥3 additional lines of therapy and 25.6% received a PD-(L)1 inhibitor after the study treatments, OS was significantly improved in the toripalimab arm (14.6 vs. 13.3 months, HR = 0.798 [95% CI: 0.648-0.982], P = 0.0327) at the final OS analysis at data cut off (20 Apr 2023). WES results from 300 patients showed that improvements in PFS and OS were similar irrespective of TMB status. Genomic alterations in integrin-mediated focal adhesion complex were associated with poor prognosis for both PFS and OS in the toripalimab arm. Toripalimab plus chemotherapy had a manageable safety profile, with no new safety signals observed. The addition of toripalimab to chemotherapy provided significant improvements in PFS and OS for patients with ES-SCLC with an acceptable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
螺旋飞天放屁完成签到,获得积分10
刚刚
刚刚
细腻巨人完成签到 ,获得积分10
1秒前
自信的冬日完成签到,获得积分10
1秒前
百里丹珍完成签到,获得积分10
2秒前
洋芋二号发布了新的文献求助10
2秒前
传奇3的应助被四辈采纳,获得10
2秒前
NexusExplorer的应助被汤汤采纳,获得10
3秒前
听枫完成签到,获得积分10
3秒前
yong完成签到,获得积分10
4秒前
Jiaaaa完成签到,获得积分10
4秒前
HEH发布了新的文献求助10
4秒前
hou的应助被尾气是菠萝口味采纳,获得10
5秒前
张津浩完成签到,获得积分10
5秒前
深情的依风完成签到,获得积分10
5秒前
依壹完成签到,获得积分10
5秒前
张铁柱完成签到,获得积分10
5秒前
Cakoibao的应助被ZYC007采纳,获得10
5秒前
花开富贵完成签到,获得积分10
5秒前
赵丽莹完成签到,获得积分10
6秒前
Poisomber完成签到,获得积分10
6秒前
6秒前
李李玲发布了新的文献求助10
6秒前
化学学渣完成签到,获得积分10
6秒前
GGbond完成签到,获得积分10
7秒前
samxie完成签到,获得积分10
7秒前
泽雾川完成签到,获得积分10
7秒前
txinlanc完成签到,获得积分10
7秒前
青橙发布了新的文献求助20
8秒前
研友_Lw7MKL完成签到,获得积分10
8秒前
早起完成签到,获得积分10
8秒前
王春来完成签到,获得积分10
9秒前
Broxiga完成签到,获得积分10
9秒前
研友_VZG7GZ的应助被整齐的手机采纳,获得10
9秒前
BAEKHYUNLUCKY完成签到,获得积分10
9秒前
小海绵发布了新的文献求助10
10秒前
komorebi完成签到,获得积分10
10秒前
华仔的应助被呜呼采纳,获得10
10秒前
俏皮秋烟完成签到,获得积分10
10秒前
冀晓梦完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152197
求助须知:如何正确求助?哪些是违规求助? 9548933
关于积分的说明 21688809
捐赠科研通 7740419
什么是DOI,文献DOI怎么找? 3425136
关于科研通互助平台的介绍 2550342
邀请新用户注册赠送积分活动 2468584